University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

Lung Ultrasound in Children With Severe Malaria

Completed

Conditions: Severe Malaria

Interventions: Device: lung ultrasound

First Posted Date: 2019-11-25

Last Posted Date: 2022-06-22

Lead Sponsor: University of Oxford

Target Recruit Count: 124

Registration Number: NCT04176029

Locations: 🇨🇩
The Maluku District Hospital, Kinshasa, Congo, The Democratic Republic of the

Citalopram and Self Emotional Processing

Not Applicable

Conditions: Depression
Mental Disorder
Cognition
Antidepressive Agents
Molecular Mechanisms of Pharmacological Action
Depressive Disorder

Interventions: Drug: Placebo oral tablet
Drug: Citalopram

First Posted Date: 2019-11-19

Last Posted Date: 2019-11-19

Lead Sponsor: University of Oxford

Target Recruit Count: 44

Registration Number: NCT04169230

Locations: 🇬🇧
University of Oxford, Oxford, United Kingdom

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

Phase 1

Terminated

Conditions: Rabies

Interventions: Biological: ChAdOx2 RabG
Biological: Inactivated Rabies Vaccine

First Posted Date: 2019-11-14

Last Posted Date: 2024-11-08

Lead Sponsor: University of Oxford

Target Recruit Count: 18

Registration Number: NCT04162600

Locations: 🇬🇧
CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Citalopram and Stress Reactivity

Not Applicable

Conditions: Antidepressive Agents
Cognition
Stress
Depression
Depressive Disorder
Mental Disorder

Interventions: Drug: Citalopram
Other: Placebo

First Posted Date: 2019-11-13

Last Posted Date: 2019-11-15

Lead Sponsor: University of Oxford

Target Recruit Count: 40

Registration Number: NCT04161209

Locations: 🇬🇧
University of Oxford, Oxford, United Kingdom

Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV

Completed

Conditions: Cervical Cancer
HPV Infection
HIV Infections

First Posted Date: 2019-11-07

Last Posted Date: 2022-05-24

Lead Sponsor: University of Oxford

Target Recruit Count: 71

Registration Number: NCT04155294

Locations: 🇬🇧
Oxford University Hospital NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
🇬🇧
Buckinghamshire Healthcare NHS Trust, High Wycombe, United Kingdom
🇬🇧
Royal Free Hospital Nhs Foundation Trust, London, United Kingdom

and more 3 locations

Tofacitinib in Depression (TIDE)

Phase 1

Terminated

Conditions: Inflammation
Depression

Interventions: Drug: Tofacitinib 5 MG [Xeljanz]
Other: Placebo

First Posted Date: 2019-10-28

Last Posted Date: 2022-08-09

Lead Sponsor: University of Oxford

Target Recruit Count: 2

Registration Number: NCT04141904

Locations: 🇬🇧
Department of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

Oxford Study of Quantification in Parkinsonism

Conditions: Progressive Supranuclear Palsy
Parkinson Disease

First Posted Date: 2019-10-25

Last Posted Date: 2020-12-11

Lead Sponsor: University of Oxford

Target Recruit Count: 300

Registration Number: NCT04139551

Locations: 🇬🇧
John Radcliffe Hospital, Headington, Please Select, United Kingdom

VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine

Phase 1

Terminated

Conditions: Malaria,Falciparum

Interventions: Biological: Pfs25-IMX313/Matrix-M1

First Posted Date: 2019-10-17

Last Posted Date: 2020-09-29

Lead Sponsor: University of Oxford

Target Recruit Count: 1

Registration Number: NCT04130282

Locations: 🇬🇧
CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Selegiline and Reward Processing

Not Applicable

Conditions: Healthy

Interventions: Drug: Selegiline Hydrochloride 10 MG
Drug: Placebo

First Posted Date: 2019-10-17

Last Posted Date: 2019-10-17

Lead Sponsor: University of Oxford

Target Recruit Count: 54

Registration Number: NCT04130087

Locations: 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease

Phase 1

Terminated

Conditions: Alzheimer Disease
Mild Cognitive Impairment

Interventions: Other: Placebo
Drug: JNJ-40346527

First Posted Date: 2019-10-09

Last Posted Date: 2024-05-09

Lead Sponsor: University of Oxford

Target Recruit Count: 2

Registration Number: NCT04121208

Locations: 🇬🇧
South London and Maudsley Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom
🇬🇧
Oxford Health NHS Trust, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy